Characteristics of patients who received a URD transplant
| Variable . | Cy/ATG/TBI 200 cGy* . | Flu/Cy/ATG/TBI 200 cGy† . | Flu/Cy/ATG‡ . | Cy/ATG§ . |
|---|---|---|---|---|
| N | 120 | 172 | 66 | 51 |
| Age, median (range), y | 21 (2-59) | 19 (1-59) | 16 (1-60) | 21 (2-57) |
| Age category, y | ||||
| <18 | 41 (34) | 82 (48) | 37 (56) | 18 (35) |
| 18-29 | 44 (37) | 52 (30) | 15 (23) | 15 (29) |
| ≥30 | 35 (29) | 38 (22) | 14 (21) | 18 (35) |
| Sex | ||||
| Male | 60 (50) | 85 (49) | 38 (58) | 24 (47) |
| Female | 60 (50) | 87 (51) | 28 (42) | 27 (53) |
| Performance score | ||||
| 90-100 | 87 (73) | 131 (76) | 45 (68) | 38 (75) |
| ≤80 | 29 (24) | 38 (22) | 16 (24) | 11 (22) |
| Not reported | 4 (3) | 3 (2) | 5 (8) | 2 (4) |
| Recipient CMV serostatus | ||||
| Positive | 83 (69) | 105 (61) | 35 (53) | 35 (69) |
| Negative | 35 (29) | 66 (38) | 31 (47) | 15 (29) |
| Not reported | 2 (2) | 1 (< 1) | — | 1 (2) |
| Interval diagnosis to transplant, mo | ||||
| ≤12 | 59 (49) | 98 (57) | 27 (41) | 28 (55) |
| >12 | 61 (51) | 74 (43) | 39 (59) | 23 (45) |
| Donor–recipient HLA match | ||||
| 8/8 allele-level match | 97 (81) | 129 (75) | 55 (83) | 37 (73) |
| 7/8 allele-level match | 23 (19) | 43 (25) | 11 (17) | 14 (27) |
| Donor–recipient sex match | ||||
| Female to male | 18 (15) | 23 (13) | 7 (11) | 3 (6) |
| Other | 102 (85) | 149 (87) | 59 (89) | 48 (94) |
| GVHD prophylaxis | ||||
| Cyclosporine + methotrexate | 72 (60) | 30 (45) | 97 (56) | 29 (57) |
| Cyclosporine + mycophenolate | 2 (2) | 3 (5) | 9 (5) | 3 (6) |
| Cyclosporine alone | 3 (3) | 2 (3) | 11 (6) | 2 (4) |
| Tacrolimus + methotrexate | 37 (31) | 20 (30) | 55 (32) | 12 (24) |
| Tacrolimus + mycophenolate | 6 (5) | 11 (17) | — | 5 (10) |
| Transplant period | ||||
| 2000-2004 | 28 (23) | — | 6 (9) | 9 (18) |
| 2005-2008 | 42 (35) | 38 (22) | 16 (24) | 10 (20) |
| 2009-2014 | 50 (42) | 134 (78) | 44 (67) | 32 (63) |
| Follow-up, median (range), mo | 71 (4-169) | 46 (12-121) | 60 (6-198) | 48 (13-192) |
| Variable . | Cy/ATG/TBI 200 cGy* . | Flu/Cy/ATG/TBI 200 cGy† . | Flu/Cy/ATG‡ . | Cy/ATG§ . |
|---|---|---|---|---|
| N | 120 | 172 | 66 | 51 |
| Age, median (range), y | 21 (2-59) | 19 (1-59) | 16 (1-60) | 21 (2-57) |
| Age category, y | ||||
| <18 | 41 (34) | 82 (48) | 37 (56) | 18 (35) |
| 18-29 | 44 (37) | 52 (30) | 15 (23) | 15 (29) |
| ≥30 | 35 (29) | 38 (22) | 14 (21) | 18 (35) |
| Sex | ||||
| Male | 60 (50) | 85 (49) | 38 (58) | 24 (47) |
| Female | 60 (50) | 87 (51) | 28 (42) | 27 (53) |
| Performance score | ||||
| 90-100 | 87 (73) | 131 (76) | 45 (68) | 38 (75) |
| ≤80 | 29 (24) | 38 (22) | 16 (24) | 11 (22) |
| Not reported | 4 (3) | 3 (2) | 5 (8) | 2 (4) |
| Recipient CMV serostatus | ||||
| Positive | 83 (69) | 105 (61) | 35 (53) | 35 (69) |
| Negative | 35 (29) | 66 (38) | 31 (47) | 15 (29) |
| Not reported | 2 (2) | 1 (< 1) | — | 1 (2) |
| Interval diagnosis to transplant, mo | ||||
| ≤12 | 59 (49) | 98 (57) | 27 (41) | 28 (55) |
| >12 | 61 (51) | 74 (43) | 39 (59) | 23 (45) |
| Donor–recipient HLA match | ||||
| 8/8 allele-level match | 97 (81) | 129 (75) | 55 (83) | 37 (73) |
| 7/8 allele-level match | 23 (19) | 43 (25) | 11 (17) | 14 (27) |
| Donor–recipient sex match | ||||
| Female to male | 18 (15) | 23 (13) | 7 (11) | 3 (6) |
| Other | 102 (85) | 149 (87) | 59 (89) | 48 (94) |
| GVHD prophylaxis | ||||
| Cyclosporine + methotrexate | 72 (60) | 30 (45) | 97 (56) | 29 (57) |
| Cyclosporine + mycophenolate | 2 (2) | 3 (5) | 9 (5) | 3 (6) |
| Cyclosporine alone | 3 (3) | 2 (3) | 11 (6) | 2 (4) |
| Tacrolimus + methotrexate | 37 (31) | 20 (30) | 55 (32) | 12 (24) |
| Tacrolimus + mycophenolate | 6 (5) | 11 (17) | — | 5 (10) |
| Transplant period | ||||
| 2000-2004 | 28 (23) | — | 6 (9) | 9 (18) |
| 2005-2008 | 42 (35) | 38 (22) | 16 (24) | 10 (20) |
| 2009-2014 | 50 (42) | 134 (78) | 44 (67) | 32 (63) |
| Follow-up, median (range), mo | 71 (4-169) | 46 (12-121) | 60 (6-198) | 48 (13-192) |
Values are n (%) unless otherwise noted.
Cy dose: 200 mg/kg (n = 97), 150 mg/kg (n = 17), 100 mg/kg (n = 4), 50 mg/kg (n = 2).
Cy dose: 200 mg/kg (n = 2), 150 mg/kg (n = 37), 100 mg/kg (n = 76), 50 mg/kg (n = 57).
Cy dose: 200 mg/kg (n = 25), 150 mg/kg (n = 1), 100 mg/kg (n = 23), 50 mg/kg (n = 17).
Cy dose: 200 mg/kg (n = 42), 100 mg/kg (n = 5), 100 mg/kg (n = 1), 50 mg/kg (n = 3).